ArticleJournal of molecular modeling2026
Computational Modeling and MM-PBSA-Based Molecular Dynamics Investigation of Unexplored tRNA Isoleucine Lysidine Synthetase from Mycobacterium tuberculosis with Hyperbranched Amoxicilloyl-Poly-L-Lysine.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextIntegrated in-silico approach employed to characterize tRNA isoleucine lysidine synthetase enzyme (MtTilS; UniProt P9WG52), which is essential for protein synthesis in Mycobacterium tuberculosis and to design Amoxicilloyl-Poly-L-Lysine (APL) compounds as putative inhibitors. MtTilS (323 aa) contained TilS (9-230), substrate-binding (249-323) domains and conserved SGGXDS motif. Homology modeling revealed Rossmann-like α/β/α fold, favourable validation (ERRAT 96%, VERIFY3D 81.8%, ProSA - 9.96) and positively charged N-terminal groove (druggability ~ 0.8). APL compounds showed predicted antibacterial activity, high aqueous solubility and low predicted toxicity. Docking prioritized APL-3 (- 7.0 kcal/mol) as favourable inhibitor. Three independent 200 ns molecular dynamics simulations showed preservation of protein fold and ligand association. Cluster analysis indicated convergence toward dominant conformational states. Principal component analysis (PCA) showed broader but reproducible conformational sampling. Free energy landscape (FEL) analysis identified low-energy conformational basins. Dynamic cross-correlation matrix (DCCM) analysis showed conserved correlated residue motions. MM-PBSA indicated favourable binding free energy (-60.0 ± 24.6 kJ/mol) with van der Waals and electrostatic interactions as major contributors while Arg101, Met145, Tyr105, Arg146, Arg140 and Arg219 as major energetic contributors. Preliminary computational evidence supporting MtTilS as target and APL-3 as putative inhibitor candidate necessitating further experimental validation.
methodsMtTilS sequence analyzed using CDD, BLAST and MEGA-X. Structure modeled with Phyre2 minimized using Swiss-PDB Viewer/GROMOS96, validated with SAVES-6.0 and visualized in PyMOL-2.0. Binding pockets and druggability predicted using HDOCK and DoGSiteScorer. APL designed in Avogadro (MMFF94) and screened using AntiBac-Pred. ADME/toxicity assessed using SwissADME and ProTox-II. Docking performed with AutoDock Vina-1.2.0 and MD using GROMACS (CHARMM36ff). Trajectories analyzed by PCA, FEL, DCCM and MM/PBSA.
Indexed as
Identifiers
42762338What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.